Biologics for Psoriasis
As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review material.
This study material discusses the current US Food and Drug Administration–approved biologic medications for psoriasis and psoriatic arthritis, including the mechanism of action, dosing, and side effects.
Practice Question Answers
1. Which biologic is administered as an intravenous infusion?
a. adalimumab
,b. etanercept
c. infliximab
d. secukinumab
e. ustekinumab
2. Which biologic is dosed based on body weight?
a. adalimumab
b. etanercept
c. infliximab
d. secukinumab
e. ustekinumab
3. Which biologic has been shown to worsen existing Crohn disease?
a. adalimumab
b. etanercept
c. infliximab
d. secukinumab
e. ustekinumab
4. Which biologic is a fusion protein?
a. adalimumab
b. etanercept
c. infliximab
d. secukinumab
e. ustekinumab
5. Which biologic has been shown to cause reversible posterior leukoencephalopathy syndrome?
a. adalimumab
b. etanercept
c. infliximab
d. secukinumab
e. ustekinumab
